Argireline

Argireline was developed by Lipotec (now Lubrizol Life Science) and introduced commercially in 2002 as the first peptide cosmetic alternative to botulinum toxin (Botox). It targets the same molecular machinery as Botox — the SNARE protein complex responsible for acetylcholine vesicle fusion at neuromuscular junctions — but through competitive inhibition rather than irreversible cleavage.

Clinical studies using 10% Argireline solution showed 17–27% reduction in expression wrinkle depth around the eyes and forehead over 30 days of twice-daily application. While significantly less potent than Botox, Argireline provides a partial, reversible effect that can be maintained continuously, making it suitable for cosmetic products targeting prevention of wrinkle formation.

// SNARE COMPLEX COMPETITIVE INHIBITION

Argireline's sequence mimics the N-terminal domain of SNAP-25, a component of the SNARE complex that drives synaptic vesicle docking and fusion. By competing with SNAP-25 for SNARE complex assembly, Argireline reduces the efficiency of acetylcholine vesicle exocytosis, partially relaxing facial muscle contraction. Unlike botulinum toxin, this inhibition is competitive (concentration-dependent) and fully reversible.

// CATECHOLAMINE RELEASE INHIBITION

Argireline also inhibits catecholamine release from adrenal chromaffin cells — an in vitro mechanism that may contribute to reduced adrenergic signaling in facial vasomotor nerves, providing a secondary mechanism for expression line reduction.